- About
- Organization
- Organization Overview
- Dean’s Office
- Department of Bioengineering and Therapeutic Sciences
- Department of Clinical Pharmacy
- Department of Pharmaceutical Chemistry
- Quantitative Biosciences Institute
- Org Chart
- Research
- Education
- Patient Care
- People
- News
- Events
Five School of Pharmacy trainees earn honors from the American Society for Clinical Pharmacology & Therapeutics
By UCSF School of Pharmacy Editorial Staff / Tue Dec 14, 2021
Wikimedia Commons
Five trainees in the UCSF School of Pharmacy have earned the 2022 Presidential Trainee Award from the American Society for Clinical Pharmacology & Therapeutics (ASCPT) in recognition of the outstanding quality of their research endeavors.
The trainees, ranging from PhD students to postdoctoral researchers, were among 21 individuals from around the U.S. who earned the highest scores among abstracts accepted for presentation at ASCPT’s annual conference.
Awardees will first be honored during ASCPT’s Network and Community Experience from January 10–14, 2022. They will also be acknowledged at the ASCPT 2022 Annual Meeting during the Showcase of Top Trainee Abstracts on Wednesday, March 16 from 6:15–7:15 p.m., and their posters will be on display for the entire duration of the meeting.
Congratulations to Mari, Agathe, Vincent, Emma, and Huy!
|
Agathe Béranger, MD, PhD Postdoctoral researcher, Savic Lab Developmental pharmacokinetics and pharmacogenomics of isoniazid in predominantly low-birth-weight or preterm infants with or without HIV exposure |
|
Mari Cayabyab, PharmD ’20 UCSF Clinical Pharmacology and Therapeutics Postdoctoral Training Program, Oni-Orisan Lab 2022 Jason Morrow, MD Presidential Trainee Award Recipient Coronary heart disease polygenic risk score modifies statin relative risk reduction for the primary prevention of myocardial infarction in a real-world cohort |
|
Vincent Chang, BSc PhD student in Pharmaceutical Sciences and Pharmacogenomics (PSPG), Savic Lab Pharmacokinetic and pharmacodynamic analysis of primary clinical outcomes in treating drug-sensitive tuberculosis with four-month high-dose rifapentine with and without moxifloxacin (Study 31/A5349) |
|
Emma Hughes, BA PhD student in Pharmaceutical Sciences and Pharmacogenomics (PSPG), Savic and Aweeka Labs Optimizing dihydroartemisinin-piperaquine regimens for malaria prevention in pregnant women using repeated ECG and parasite density measures |
|
Huy Ngo, PharmD, PhD Postdoctoral researcher, Giacomini Lab Weight-based dosing is not needed for rifampicin for patients with tuberculosis (TB): PK evidence from TBTC Study 31/A5349 |
More
Data-driven drug dosing speeds tuberculosis treatment to four months
Tags
Category:
Sites:
School of Pharmacy, Department of Bioengineering and Therapeutic Sciences, Department of Clinical Pharmacy, PharmD Degree Program
About the School: The UCSF School of Pharmacy aims to solve the most pressing health care problems and strives to ensure that each patient receives the safest, most effective treatments. Our discoveries seed the development of novel therapies, and our researchers consistently lead the nation in NIH funding. The School’s doctor of pharmacy (PharmD) degree program, with its unique emphasis on scientific thinking, prepares students to be critical thinkers and leaders in their field.
Related news
- Update from the Dean: Passing the torch
- Data-driven drug dosing speeds tuberculosis treatment to four months
- Dresser elected president of the American Society for Clinical Pharmacology & Therapeutics
- Benet honored for lifetime accomplishments in drug clearance research and discovery
- Oni-Orisan given the Darrell Abernethy Early Stage Investigator Award
Recent news
Share your news
Faculty and staff: We want to hear about the work that you are engaged in, such as honors and awards received, publications, and events featuring you.